drugset
drugset / Trial / NCT05433116

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

NCT05433116 ↗

Phase 2 Active not recruiting 50 enrolled Saarland University
RandomizedSingle-groupOpen-labelTreatment

Summary

Open-label, two-arm, prospective multicenter phase II clinical trial to determine the efficacy and safety of combined pembrolizumab and lenvatinib compared to pembrolizumab alone as maintenance therapy after definitive radiochemotherapy of locally advanced head and neck squamous cell carcinoma (HNSCC).

Timeline

Start
2023-05-25
Primary completion
2026-01
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 20 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

head and neck squamous cell carcinoma